Peptide Library / Detail
ARA-290
Half-life
Short (~20 minutes after SC; minutes after IV), with pharmacodynamic effects outlasting plasma exposure
Delivery
Subcutaneous injection (e.g., once daily in 28-day study designs); IV used in early PK work.
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
ARA-290 (cibinetide) is an 11–amino acid peptide engineered from erythropoietin’s helix-B that selectively activates the EPOR–CD131 ‘innate repair receptor’ to promote tissue protection, anti-inflammatory signaling, and small-fiber nerve repair without stimulating erythropoiesis.
Usage
Studied in small fiber neuropathy (e.g., sarcoidosis-associated and type 2 diabetes), ocular/ischemic injury models, and inflammatory conditions to evaluate symptom relief, nerve fiber regeneration, and improved metabolic/quality-of-life outcomes.
Mechanism of Action
Binds the EPOR–CD131 heteroreceptor (innate repair receptor), triggering JAK2/STAT and PI3K/Akt pathways while suppressing NF-κB–mediated inflammation; restores tissue homeostasis and supports small-fiber nerve regrowth.
Benefits(5)
- Reduces neuropathic pain and autonomic symptoms in SFN studies
- Improves quality-of-life measures
- Increases corneal small-fiber nerve density in clinical imaging
- Anti-inflammatory, cytoprotective effects without erythropoiesis
- Metabolic improvements noted in type 2 diabetes cohorts
Side Effects(3)
- Generally well tolerated in trials
- Mild injection-site reactions
- No meaningful changes in hematocrit/hemoglobin (non-erythropoietic)
ARA-290 — frequently asked questions
What is ARA-290?
ARA-290 (cibinetide) is an 11–amino acid peptide engineered from erythropoietin’s helix-B that selectively activates the EPOR–CD131 ‘innate repair receptor’ to promote tissue protection, anti-inflammatory signaling, and small-fiber nerve repair without stimulating erythropoiesis.
What is the half-life of ARA-290?
ARA-290 has an approximate half-life of Short (~20 minutes after SC; minutes after IV), with pharmacodynamic effects outlasting plasma exposure. The half-life determines how often you need to inject to maintain steady blood levels — use the Peptides Calculator half-life calculator to plot your specific dosing schedule and see the decay curve.
How is ARA-290 administered?
ARA-290 is typically delivered via subcutaneous injection (e.g., once daily in 28-day study designs); iv used in early pk work.. The Peptides Calculator app helps you reconstitute the vial with bacteriostatic water, calculate your exact dose in syringe units, and track each injection.
How does ARA-290 work?
Binds the EPOR–CD131 heteroreceptor (innate repair receptor), triggering JAK2/STAT and PI3K/Akt pathways while suppressing NF-κB–mediated inflammation; restores tissue homeostasis and supports small-fiber nerve regrowth.
What are the researched benefits of ARA-290?
Studied benefits of ARA-290 include: Reduces neuropathic pain and autonomic symptoms in SFN studies, Improves quality-of-life measures, Increases corneal small-fiber nerve density in clinical imaging, Anti-inflammatory, cytoprotective effects without erythropoiesis, Metabolic improvements noted in type 2 diabetes cohorts. These are research findings only — Peptides Calculator does not provide medical advice; consult a qualified healthcare professional before starting any peptide protocol.
What are the side effects of ARA-290?
Reported side effects of ARA-290 include: Generally well tolerated in trials, Mild injection-site reactions, No meaningful changes in hematocrit/hemoglobin (non-erythropoietic). Always discuss potential side effects with a licensed healthcare provider before using any research peptide.
Related peptides
Other peptide compounds in the Peptides Calculator library.
Sema GLP-1
Half-life · About 7 days
Oxytocin
Half-life · ≈3–5 minutes
Selank
Half-life · 3–10 minutes in plasma, longer central nervous effects
Thymosin Alpha 1
Half-life · 2 hours (approx.)
Tesofensine Powder
Half-life · Approximately 8 days
Adipotide
Half-life · 2–4 hours (in animal studies; human data not established)